Skip to main content
Premium Trial:

Request an Annual Quote

Caprotec Raises Nearly $9M in Two Private Financings

NEW YORK (GenomeWeb News) – Caprotec Bioanalytics announced today that it has received a total of €6 million ($8.8 million) from two rounds of private financing to support further development and marketing of the firm’s Capture Compound Mass Spectrometry technology for analyzing complex protein mixtures.
 
Investors in the two rounds included Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and private investors including Heinrich-Maria Schulte, co-founder of Evotec and owner of the Wölbern Bank in Hamburg, Germany.
 
According to Berlin-based Caprotec, the CCMS technology enables targeted isolation of proteins or protein classes directly from a complex biological sample. The captured proteins are then identified and characterized by mass spectrometry.
 
“Our platform closes a technological gap in the field of proteome analysis with its ability to be applied in both water-soluble and membrane protein mixtures,” said Caprotec CEO and Founder Hubert Köster.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.